Journal of Infectious Diseases & Preventive Medicine
Open Access

CJSC Biotechnology Developments, Human Stem Cells Institute, Moscow, Russian Federation

Biography

Dr. Igor V. Krasilnikov is a distinguished scientist and executive in the field of biotechnology, serving as the CEO of CJSC Biotechnology Developments and a professor at the Human Stem Cells Institute in Moscow, Russia. With extensive expertise in vaccine development, gene engineering, and biotechnology, Dr. Krasilnikov has made significant contributions to medical science and public health.CEO, CJSC Biotechnology Developments: Under Dr. Krasilnikov's leadership, the company focuses on innovative biotechnological solutions, including the development of vaccines and therapeutic agents.professor, Human Stem Cells Institute: In his academic role, Dr. Krasilnikov mentors researchers and contributes to advancing stem cell research and its applications in regenerative medicine.Dr. Krasilnikov's research encompasses: Vaccine development, particularly for viral diseases such as COVID-19 and influenza. Gene engineering and biotechnology applications in medicine. Development of virus-like particle (VLP) vaccines and adjuvants.

Publications

• Research Article   
  TetraFluBet: A Tetravalent Influenza Vaccine Enhanced with Natural Betulin Adjuvant
  Author(s): Irina Tcymbarevich, Anna Krasheninnikova, Maria Sukhova, Aleksandr Ivanov, Marina Stukova, Ekaterina Romanovskaya-Romanko, Nataliya Mikhailova, Anton Belkin, Olga Belyakova, Alevtina Nicolaeva and Igor Krasilnikov*
  
  Influenza is well-known to have a considerable influence on the healthcare system; therefore, vaccination plays a significant role in dealing with severe consequences. Close attention is paid to the development of tetravalent adjuvanted vaccines containing antigens of two influenzas A subtypes (H1N1, H3N2) and two influenza B subtypes (Victoria, Yamagata) to increase the effectiveness of influenza prevention. In this work, we present the results of an animal study of an innovative subunit tetravalent candidate influenza vaccine with the addition of betulin as an adjuvant, TetraFluBet. The study was conducted using female BALB/c mice, male and female mongrel rats, and guinea pigs. TetraFluBet was injected intraperitoneally twice in a 14-day interval prior to intranasal infection with 100LD50. Sub-chronic toxicity was assessed by immunohistochemistry of extracted organs and by hematolog.. View More»
  DOI: 10.35841/2329-8731.24.12.371

  Abstract HTML PDF

Other relevant publications from this author

• https://www.mdpi.com/2076-393X/11/2/326?utm_source=chatgpt.com

  https://europepmc.org/article/MED/35062730?utm_source=chatgpt.com

  https://www.mdpi.com/2076-393X/10/8/1290?utm_source=chatgpt.com